Sarepta (SRPT) calls active after FDA approves eteplirsen
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet (GOOGL) January weekly volatility increases into Q4 and outlook
- iPath S&P 500 VIX ST Futures ETN (VXX) down 16c to 20.57
- Options with increasing volume: FNSR P GPL QCOM RAD
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!